Version 1
: Received: 4 July 2023 / Approved: 4 July 2023 / Online: 5 July 2023 (11:22:42 CEST)
How to cite:
Tokarzewicz, A.; Oldak, L.; Młynarczyk, G.; Klekotka, U.; Gorodkiewicz, E. Developing of a New Analytical Tool for Quantification of Fibroblast Growth Factor-23 – SPRi Biosensor.. Preprints2023, 2023070278. https://doi.org/10.20944/preprints202307.0278.v1
Tokarzewicz, A.; Oldak, L.; Młynarczyk, G.; Klekotka, U.; Gorodkiewicz, E. Developing of a New Analytical Tool for Quantification of Fibroblast Growth Factor-23 – SPRi Biosensor.. Preprints 2023, 2023070278. https://doi.org/10.20944/preprints202307.0278.v1
Tokarzewicz, A.; Oldak, L.; Młynarczyk, G.; Klekotka, U.; Gorodkiewicz, E. Developing of a New Analytical Tool for Quantification of Fibroblast Growth Factor-23 – SPRi Biosensor.. Preprints2023, 2023070278. https://doi.org/10.20944/preprints202307.0278.v1
APA Style
Tokarzewicz, A., Oldak, L., Młynarczyk, G., Klekotka, U., & Gorodkiewicz, E. (2023). Developing of a New Analytical Tool for Quantification of Fibroblast Growth Factor-23 – SPRi Biosensor.. Preprints. https://doi.org/10.20944/preprints202307.0278.v1
Chicago/Turabian Style
Tokarzewicz, A., Urszula Klekotka and Ewa Gorodkiewicz. 2023 "Developing of a New Analytical Tool for Quantification of Fibroblast Growth Factor-23 – SPRi Biosensor." Preprints. https://doi.org/10.20944/preprints202307.0278.v1
Abstract
A new biosensor based on Surface Plasmon Resonance Imaging detection technique for quantitative determination of Fibroblast Growth Factor-23 has been developed. The FGF-23 is mainly produced in the bone tissues as a phosphaturic hormone that upon secretion creates a trimeric complex with FGF receptor 1 and αKlotho. FGF-23 acts on the kidneys: it stimulates phosphate excretion and suppresses formation of active vitamin D. It has been proven that FGF-23 plays a role in bones’ carcinogenesis and its metastasis. The newly developed method based on the SPRi biosensor has been validated – the precision and accuracy as well as selectivity were acceptable and gave less than ±10% of recovery. The linear response of the biosensor ranges 1– 75 pg/ml. The limit of detection was 0.033 pg/ml and limit of quantification was 0.107 pg/ml. The biosensor was used to determine FGF-23 concentration in the plasma of healthy individuals as well as in the plasma of the patients with the clear cell carcinoma of the kidneys. The obtained results were compared with the results of the ELISA measurements. The determined Pearson correlation coefficients were close to 1 what showed that the newly developed biosensor can be used as the competitive method to the ELISA.
Chemistry and Materials Science, Medicinal Chemistry
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
